Pfizer Restructuring charges and certain acquisition-related costs decreased by 83.5% to $100.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 85.3%, from $678.00M to $100.00M. Over 4 years (FY 2021 to FY 2025), Restructuring charges and certain acquisition-related costs shows an upward trend with a 17.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High costs signal significant corporate transformation or integration efforts, which may lead to future margin improvements once the restructuring is complete.
Non-recurring charges associated with organizational restructuring, workforce reductions, facility consolidations, and i...
Reported by most large-cap companies undergoing M&A or cost-optimization programs as 'special items' or 'restructuring charges'.
pfe_restructuring_and_acquisition_costs| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.00M | $646.00M | $135.00M | $192.00M | $189.00M | $199.00M | $795.00M | $9.00M | $214.00M | $155.00M | $2.57B | $102.00M | $1.25B | $313.00M | $750.00M | $678.00M | -$18.00M | $286.00M | $605.00M | $100.00M |
| QoQ Change | — | >999% | -79.1% | +42.2% | -1.6% | +5.3% | +299.5% | -98.9% | >999% | -27.6% | >999% | -96.0% | >999% | -75.0% | +139.6% | -9.6% | -102.7% | >999% | +111.5% | -83.5% |
| YoY Change | — | — | — | — | >999% | -69.2% | +488.9% | -95.3% | +13.2% | -22.1% | +222.8% | >999% | +486.0% | +101.9% | -70.8% | +564.7% | -101.4% | -8.6% | -19.3% | -85.3% |